The Wilms' Tumor Gene Product (WT1) Modulates the Response to 1,25-Dihydroxyvitamin D3 by Induction of the Vitamin D Receptor

Ulrich Maurer, Frédéric Jehan, Christoph Englert, Gabriele Hübinger, Eckhart Weidmann, Hector F. DeLuca, Lothar Bergmann

Journal of Biological Chemistry · 2001 · 50 citations · 26 references

DOIFull text

Open access

Concepts

Abstract

The Wilms' tumor gene (wt1) encodes a transcription factor involved in urogenital development, in particular in renal differentiation, and in hematopoietic differentiation. Differentiation of a number of solid tumor and leukemic cells lines can be mediated by 1,25-dihydroxyvitamin D3. This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D3, the vitamin D receptor (VDR). In initial experiments addressing a possible link between WT1 and VDR, we observed a correlated expression of WT1 and VDR mRNA in samples from renal tissues. HT29 colon carcinoma cells, stably transfected to express WT1, exhibited elevated endogenous VDR levels compared with control cells transfected with a control construct. Elevated VDR expression was found in wt1-transfected human embryonic kidney 293 cells, as well. In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1. The responsive sequence element was specifically bound by wild-type, but not by mutated WT1, in electrophoretic mobility shift assays. HT29 colon carcinoma cells, which respond to 1,25-dihydroxyvitamin D3 with slow induction of growth arrest, were investigated for the influence of WT1 on 1,25-dihydroxyvitamin D3-mediated growth suppression. Although HT29 cells transfected with a control construct responded moderately to 1,25-dihydroxyvitamin D3, the response of HT29 cells expressing WT1 was strikingly enhanced. Stimulation with dihydroxyvitamin D3 caused an up to 3-fold reduction in the growth rate of different HT29 clones expressing WT1 as compared with control cells lacking WT1 expression. Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D3. We conclude that the vitamin D receptor gene is a target for transcriptional activation by WT1, suggesting a possible physiological role of this regulatory pathway. The Wilms' tumor gene (wt1) encodes a transcription factor involved in urogenital development, in particular in renal differentiation, and in hematopoietic differentiation. Differentiation of a number of solid tumor and leukemic cells lines can be mediated by 1,25-dihydroxyvitamin D3. This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D3, the vitamin D receptor (VDR). In initial experiments addressing a possible link between WT1 and VDR, we observed a correlated expression of WT1 and VDR mRNA in samples from renal tissues. HT29 colon carcinoma cells, stably transfected to express WT1, exhibited elevated endogenous VDR levels compared with control cells transfected with a control construct. Elevated VDR expression was found in wt1-transfected human embryonic kidney 293 cells, as well. In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1. The responsive sequence element was specifically bound by wild-type, but not by mutated WT1, in electrophoretic mobility shift assays. HT29 colon carcinoma cells, which respond to 1,25-dihydroxyvitamin D3 with slow induction of growth arrest, were investigated for the influence of WT1 on 1,25-dihydroxyvitamin D3-mediated growth suppression. Although HT29 cells transfected with a control construct responded moderately to 1,25-dihydroxyvitamin D3, the response of HT29 cells expressing WT1 was strikingly enhanced. Stimulation with dihydroxyvitamin D3 caused an up to 3-fold reduction in the growth rate of different HT29 clones expressing WT1 as compared with control cells lacking WT1 expression. Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D3. We conclude that the vitamin D receptor gene is a target for transcriptional activation by WT1, suggesting a possible physiological role of this regulatory pathway. vitamin D receptor human embryonic kidney N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium salts kilobase WT1 recognition element In addition to its function as a regulator of calcium homeostasis, 1,25-dihydroxyvitamin D3 has been demonstrated to be a potent inducer of differentiation in leukemic cells lines and cells derived from solid tumors (reviewed in Refs. 1Jones G. Strugnell S.A. DeLuca H.F. Physiol. Rev. 1998; 78: 1193-1231Crossref PubMed Scopus (1040) Google Scholar and 2Christakos S. Raval-Pandya M. Wernyj R.P. Yang W. Biochem. J. 1996; 316: 361-371Crossref PubMed Scopus (217) Google Scholar). Physiologically, 1,25-dihydroxyvitamin D3 directly binds to its cellular receptor, the vitamin D receptor (VDR),1 resulting in transcription factor activity of the VDR. The VDR molecule dimerizes with the retinoic X receptor and activates target genes via interaction with vitamin D response elements in vitamin D-responsive promoters (1Jones G. Strugnell S.A. DeLuca H.F. Physiol. Rev. 1998; 78: 1193-1231Crossref PubMed Scopus (1040) Google Scholar, 2Christakos S. Raval-Pandya M. Wernyj R.P. Yang W. Biochem. J. 1996; 316: 361-371Crossref PubMed Scopus (217) Google Scholar). Additionally, vitamin D response element-independent functions of 1,25-dihydroxyvitamin D3, referred to as “nongenomic signaling,” have been described, as well (3Hmama Z. Nandan D. Sly L. Knutson K.L. Herrera-Velit P. Reiner N.E. J. Exp. Med. 1999; 190: 1583-1594Crossref PubMed Scopus (164) Google Scholar). Our own previous experiments addressing the effects of 1,25-dihydroxyvitamin D3 in leukemic cells pointed to an influence of Wilms' tumor gene (wt1) expression on the induction of differentiation by 1,25-dihydroxyvitamin D3(4Maurer U. Weidmann E. Krapohl A. Schneider B. Karakas T. Bergmann L. Proc. Am. Assoc. Cancer Res. 1999; 40: 736Google Scholar). The Wilms' tumor gene (wt1) was isolated by deletion analysis and positional cloning in Wilms' tumor and WAGR (Wilms' tumor, aniridia, urogenital malformation, mental retardation) patients, leading to its definition as a tumor suppressor gene (5Call K.M. Glaser T. Ito C.Y. Buckler A.J. Pelletier J. Haber D.A. Rose E.A. Kral A. Yeger H. Lewis W.H. Jones C. Housman D.E. Cell. 1990; 60: 509-520Abstract Full Text PDF PubMed Scopus (1676) Google Scholar). The gene product contains a C-terminal zinc finger motif and a proline-glutamine-rich domain at the N terminus, similar to the early growth response-1 transcription factor (6Madden S.L. Cook D.M. Morris J.F. Gashler A. Sukhatme V.P. Rauscher F.J. Science. 1991; 253: 1550-1553Crossref PubMed Scopus (409) Google Scholar). WT1 is expressed as four alternative isoforms containing or lacking a 17-amino acid stretch (termed 17AA) encoded by an alternatively spliced exon 5 and an insertion of three amino acids between zinc fingers 3 and 4, encoded by alternative splice II, termed KTS (7Haber D.A. Sohn R.L. Buckler A.J. Pelletier J. Call K.M. Housman D.E. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 9618-9622Crossref PubMed Scopus (558) Google Scholar). Expression of WT1 has been demonstrated in the kidney, the genital ridge, fetal gonads, spleen, and mesothelium (5Call K.M. Glaser T. Ito C.Y. Buckler A.J. Pelletier J. Haber D.A. Rose E.A. Kral A. Yeger H. Lewis W.H. Jones C. Housman D.E. Cell. 1990; 60: 509-520Abstract Full Text PDF PubMed Scopus (1676) Google Scholar, 8Pritchard-Jones K. Fleming S. Davidson D. Bickmore W. Porteous D. Gosden C. Bard J. Buckler A. Pelletier J. Housman D.E. van Heiningen V. Hastie N. Nature. 1990; 346: 194-197Crossref PubMed Scopus (769) Google Scholar, 9Kreidberg J.A. Sariola H. Loring J.M. Maeda M. Pelletier J. Housman D. Jaenisch R. Cell. 1993; 74: 679-691Abstract Full Text PDF PubMed Scopus (1672) Google Scholar). The absence of kidneys and gonads in wt1 knockout mice indicates the crucial role of wt1 for urogenital development (9Kreidberg J.A. Sariola H. Loring J.M. Maeda M. Pelletier J. Housman D. Jaenisch R. Cell. 1993; 74: 679-691Abstract Full Text PDF PubMed Scopus (1672) Google Scholar). During hematopoietic differentiation, the Wilms' tumor gene is transiently expressed, as well (10Maurer U. Weidmann E. Karakas T. Hoelzer D. Bergmann L. Blood. 1997; 90: 4230-4231Crossref PubMed Google Scholar, 11Maurer U. Brieger J. Weidmann E. Mitrou P.S. Hoelzer D. Bergmann L. Exp. Hematol. 1997; 25: 945-950PubMed Google Scholar). In contrast to its proposed role as a tumor suppressor, WT1 is expressed in the majority of acute leukemias (12Bergmann L. Miething C. Maurer U. Brieger J. Karakas T. Weidmann E. Hoelzer D. Blood. 1997; 90: 1217-1225Crossref PubMed Google Scholar), suggesting that the anti-oncogenic function of WT1 is dependent on the cellular context. In initial experiments, we probed a multiple-tissue cDNA blot with probes for WT1 and VDR, observing a correlated expression pattern of VDR and WT1 mRNA. This led us investigate a possible regulation of the expression of the VDR by WT1. In this work, we demonstrate that WT1 activates the VDR promoter in vitro. We show that that engineered expression of WT1 by HT29 colon carcinoma cells, which respond moderately to 1,25-dihydroxyvitamin D3 (13Shabahang M. Buras R.R. Davoodi F. Schumaker L.M. Nauta R.J. Uskokovic M.R. Brenner R.V. Evans S.R. Cancer Res. 1994; 54: 4057-4064PubMed Google Scholar), causes enhanced VDR levels and an enhanced response to 1,25-dihydroxyvitamin D3. Induction of the VDR by WT1 is confirmed in human embryonic kidney (HEK) 293 cells from renal origin, suggesting that the VDR gene represents a downstream target of WT1. HEK293 and HT29 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. For transfection, 1 × 106 cells were seeded in a 10-cm dish, and after 24 h, they were transfected with 20 μg of expression plasmid using DOTAP transfection reagent (Roche Diagnostics, Mannheim, Germany). To generate stable transfectants, cells were selected for stable vector insertion with 500 μg/ml G418 (Life Technologies, Inc.). Clones derived from single cells were generated by limiting dilution and were analyzed for WT1 protein expression by Western blotting. 1,25-Dihydroxyvitamin D3 was prepared as a 1000× stock solution (10 μm) in ethanol. Antisense probes for VDR and WT1 mRNA were generated by polymerase chain reaction amplification of the appropriate cDNA sequences (VDR 5′, CCCAGCTCTCCATGC; VDR 3′, TGACGCGGTACTTGTAGT; WT1 5′, ACGCGCCCTACCTGCCCAG; and WT1 3′, TTCTCACTGGTCTCAGATGC; MWG Biotech, Ebersberg, Germany). The VDR amplicon (224 base pairs) was cloned in antisense orientation in pCR 3.1 (Invitrogen). The wt1 amplicon was digested withBam HI, and the resulting 154-base pair fragment was cloned into pCDNA 3 (Invitrogen) after digestion withBam HI/Eco RV. GAPDH and L32 probes (Pharmingen, San Diego, CA) were included for normalization. A multiple probe for cell cycle genes including p21 was also purchased from the manufacturer. In vitro transcription and ribonuclease protection assay was performed with a kit (Pharmingen, San Diego, CA) according to the manufacturers' instructions analyzing 20 μg of total RNA isolated with Trizol reagent (Life Technologies, Inc.). Protected RNA-RNA hybrids were separated on a 6% sequencing gel and subsequently exposed to Biomax x-ray film (Eastman Kodak, Co., Rochester, NY) or to a PhosphorImager system (Molecular Dynamics). Protein lysate was dissolved in Laemmli buffer (500 mm Tris-HCl, 100 mm dithiothreitol, 2% SDS, 0.1% bromphenol blue, 10% glycerol, pH 6.8), heated to 95 °C, and subjected to a 10% polyacrylamide gel electrophoresis. After blotting to a polyvinylidene difluoride membrane (Millipore, Bedford, MA) and blocking with skim milk (Fluka, Steinheim, Germany), the membrane was incubated with anti-WT1 C19, anti-WT1 180, or anti-VDR C-20 (all from Santa Cruz Biotechnologies) antibodies diluted 1:1000. Detection was performed by incubation with a horseradish peroxidase-conjugated anti-rabbit antibody (dilution 1: 5000), and the ECL system (both from Amersham Pharmacia Biotech). For further analysis, blots were stripped with 0.2 mglycine, pH 2.5, at 56 °C for 30 min. Different murine vitamin D receptor promoter fragments were subcloned in to a pGL2basic vector upstream of the firefly luciferase reporter gene as described elsewhere (14Jehan F. DeLuca H.F. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 10138-10143Crossref PubMed Scopus (66) Google Scholar, 15Jehan F. DeLuca H.F. Arch. Biochem. Biophys. 2000; 377: 273-283Crossref PubMed Scopus (36) Google Scholar). A mutant lacking the WT1 recognition element (WRE)-related sequence was generated by digestion of the 0.5-kb construct with Rsr II and Sma I, followed by treatment with T4 polymerase and religation. The expression constructs used were WT1+17AA-KTS, WT1+17AA+KTS (wt1B and wt1D, kindly provided by F. J. Rauscher, III, Wistar Institute, Philadelphia, PA), and WTAR, encoding a truncated protein (16Haber D.A. Buckler A.J. Glaser T. Call K.M. Pelletier J. Sohn R.L. Douglass E.C. Housman D.E. Cell. 1990; 61: 1257-1269Abstract Full Text PDF PubMed Scopus (501) Google Scholar). Thewt1 coding region was subcloned into pCDNA3 (Invitrogen). NIH 3T3 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. For transfection, 0.5 × 105 cells were seeded in a 10-cm dish and were transfected with 5 μg of expression plasmid, together with 1 μg of reporter construct using DOTAP transfection reagent (Roche Diagnostics, Mannheim, Germany) after 24 h. Transfection efficiency was determined by cotransfection of 1 μg of a renilla luciferase plasmid (pRLTK; Promega, Heidelberg, Germany). After 48 h, 20 μl of lysate were transferred to a luminescent reaction, and both firefly luciferase and renilla luciferase light activity were determined according to the manufacturers' protocol (Promega, Heidelberg, Germany) with a Lumat 9510 (Berthold, Bad Weinsberg, Germany). Electrophoretic mobility shift assay experiments were essentially done as described before (17Elser B. Kriz W. Bonventre J.V. Englert C. Witzgall R. J. Biol. Chem. 1997; 272: 27908-27912Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar). 20 ng of protein were incubated with 3000 cpm of radiolabeled double-stranded oligonucleotide. The oligos were as follows: hVDRWRE sense, AGGACTGGACCTGTGGGCGGGGCGGAG; hVDRWRE antisense, CTCCGCCCCGCCCACAGGTCCAGTCCT; mutated hVDRWRE sense, AGGACTGGACCTGCG mutated hVDRWRE antisense, sense, antisense, mutated sense, and mutated antisense, in and To investigate the of WT1 on the endogenous expression of VDR, HT29 cells expressing endogenous levels of VDR were stably transfected with expression encoding the of WT1. Expression of WT1 mRNA was in different selected HT29 clones by protection assay and blotting not and the protein expression was by Western blotting. A induction of VDR mRNA was observed in generated HT29 cell clones expressing WT1, compared with HT29 cells transfected with the vector In with the induction of VDR we observed elevated VDR protein levels in HT29 cells 1 Detection of elevated levels of VDR in different HT29 clones expressing WT1 that this was not an of In control experiments, mRNA expression of the of VDR, the retinoic X was not elevated in clones expressing WT1 not To the of VDR with a WT1 target the induction of p21 C. S. A.J. J. Haber D.A. Cancer Res. 1997; Google was investigated in HT29 cells expressing WT1 and control p21 mRNA was to a VDR in HT29 cells To investigate induction of VDR by the Wilms' tumor gene product in renal cells, human embryonic kidney 293 cells were transfected with a WT1 expression and induction of VDR was by VDR protein was elevated in HEK293 cells WT1, suggesting that WT1 VDR expression in the of renal cells To the WT1 the VDR expression at the transcriptional transient cotransfection experiments were A fragment of the vdr gene promoter to a sequence coding for the firefly luciferase was with and isoforms of WT1 and a mutant lacking the zinc finger (16Haber D.A. Buckler A.J. Glaser T. Call K.M. Pelletier J. Sohn R.L. Douglass E.C. Housman D.E. Cell. 1990; 61: 1257-1269Abstract Full Text PDF PubMed Scopus (501) Google Scholar). The VDR promoter fragment was by the but not by the of WT1. In cotransfection of the mutant the VDR promoter construct 3 The response to WT1 to be in a 3 To the sequence element responsive for WT1, the promoter construct was from of the transcriptional A 0.5-kb promoter fragment as to WT1. A to the transcription was to the suggesting that the element was in this fragment of the VDR This fragment contains four with F. DeLuca H.F. Arch. Biochem. Biophys. 2000; 377: 273-283Crossref PubMed Scopus (36) Google Scholar). The element, is similar to the sequence of the K. R. D. J. C. W. Haber D.A. Cell. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). A deletion construct lacking this exhibited response to WT1 In of a growth response-1 which is in the murine but not in the human VDR the response to WT1 not The is well between the human and the vitamin D receptor The element was for its to the WT1 protein by electrophoretic mobility shift assays. The sequence element was specifically bound by but not by the mutant of a the sequence to that WT1 activates the vdr gene expression at the transcriptional through a sequence of the vitamin D receptor promoter with transcription factor and the reporter constructs with induction by mobility shift assay by WT1 of the element similar to K. R. D. J. C. W. Haber D.A. Cell. 1999; Full Text Full Text PDF PubMed Scopus Google in the of the human and murine vitamin D receptor of the sequence of WT1 to this HT29 colon carcinoma cells have been described to be responsive to 1,25-dihydroxyvitamin D3 (13Shabahang M. Buras R.R. Davoodi F. Schumaker L.M. Nauta R.J. Uskokovic M.R. Brenner R.V. Evans S.R. Cancer Res. 1994; 54: 4057-4064PubMed Google Scholar, C. L. A. Cancer Res. 2000; 60: Google Scholar), we used cells as a for the influence of WT1 on the response to D3. Different HT29 clones expressing levels of WT1 and HT29 control cells transfected with an construct were with 1,25-dihydroxyvitamin with previous (13Shabahang M. Buras R.R. Davoodi F. Schumaker L.M. Nauta R.J. Uskokovic M.R. Brenner R.V. Evans S.R. Cancer Res. 1994; 54: 4057-4064PubMed Google Scholar), HT29 cells transfected with the control vector growth after treatment with 1,25-dihydroxyvitamin D3. In HT29 cells expressing WT1 exhibited a response to 1,25-dihydroxyvitamin after the cell in HT29 cells was compared with control HT29 cells after induction with 1,25-dihydroxyvitamin D3 this HT29 control cells and to the of the dish, HT29 cells with 1,25-dihydroxyvitamin D3 and from the of the dish The growth in cells the enhanced VDR levels in HT29 clones and a in the response to 1,25-dihydroxyvitamin D3 dependent on WT1 expression. influence of WT1 expression on the response to 1,25-dihydroxyvitamin D3 in hematopoietic cells was demonstrated by the of differentiation mediated by 1,25-dihydroxyvitamin D3 of expression of WT1 H. K. B. Rauscher III, F.J. U. 1998; PubMed Scopus Google Scholar). In initial experiments, we analyzed the expression of WT1 and the receptor gene for 1,25-dihydroxyvitamin D3, VDR, by the expression pattern of both genes using an with cDNA from different and tumor tissues. We WT1 expression predominantly in cDNA derived from kidney The VDR expression pattern the pattern of WT1, the of a regulatory link between WT1 and VDR expression in renal not as for expression of the murine vitamin D receptor F. DeLuca H.F. Arch. Biochem. Biophys. 2000; 377: 273-283Crossref PubMed Scopus (36) Google Scholar). induction of the VDR by the pattern of VDR expression in different kidney or A number of WT1 target with promoters in transient cotransfection experiments by WT1, not be to be C. Englert C. M. 1998; Scopus Google Scholar). For this the regulation of a vdr promoter reporter constructs by WT1, we on the regulation of the gene expression by different cell lines with a wt1 expression construct and for WT1 protein expression. with an induction of promoter reporter construct by the isoforms in the transient transfection the endogenous VDR expression in HT29 and HEK293 cells expressing WT1 was In HT29 clones expressing WT1, the induction of VDR mRNA expression was with the induction of the expression of p21 mRNA. The p21 cell cycle gene has been to be by WT1 C. S. A.J. J. Haber D.A. Cancer Res. 1997; Google Scholar, K. R. D. J. C. W. Haber D.A. Cell. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). After single clones transfected with the WT1 we HT29 clones stably expressing WT1 This a levels of WT1, of induction of p21 or WT1 target In we observed a growth reduction of HT29 cells expressing WT1 compared with control cells cell In HT29 colon carcinoma cells, but not HEK293 cells, were responsive to 1,25-dihydroxyvitamin D3. After induction with 1,25-dihydroxyvitamin D3, HT29 cells have been to elevated activity as a of differentiation, which is by growth and followed by a slow induction of C. L. A. Cancer Res. 2000; 60: Google Scholar). In experiments with HT29 clones expressing WT1, this response was enhanced that WT1 expression in a different the response to 1,25-dihydroxyvitamin D3. WT1 with gene expression at the transcriptional and the levels A. A. Hastie M. G. A. Proc. Natl. Acad. Sci. U. S. A. 1996; PubMed Scopus Google Scholar), the mediated predominantly by the isoforms K. D. M. A. F. van V. Hastie Cell. Full Text PDF PubMed Scopus Google Scholar). For this regulation of the VDR expression by WT1 at the transcriptional was by transient cotransfection with different murine VDR promoter reporter This led to the of a sequence element in the VDR promoter for induction of the VDR expression by WT1. This sequence element is well in the human VDR promoter H. E. S. K. E. 1997; PubMed Scopus Google Scholar). is similar to the in the promoter K. R. D. J. C. W. Haber D.A. Cell. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). This element has been to be bound by with the growth response-1 target C.Y. J. 1999; PubMed Scopus (217) Google Scholar). WT1 recognition elements in the human and murine vitamin D receptor promoters were specifically bound by WT1 in mobility shift assays. Our that WT1 the cellular receptor for 1,25-dihydroxyvitamin D3 a by which WT1 be involved in cellular differentiation. To 1,25-dihydroxyvitamin D3 is to differentiation of a number of leukemic and solid tumor cell but a physiological role of 1,25-dihydroxyvitamin D3 in cellular differentiation is (1Jones G. Strugnell S.A. DeLuca H.F. Physiol. Rev. 1998; 78: 1193-1231Crossref PubMed Scopus (1040) Google Scholar, 2Christakos S. Raval-Pandya M. Wernyj R.P. Yang W. Biochem. J. 1996; 316: 361-371Crossref PubMed Scopus (217) Google Scholar). The the that the response to 1,25-dihydroxyvitamin D3 is by the Wilms' tumor gene product which is predominantly expressed in renal and hematopoietic In hematopoietic cells, we and have found that WT1 the induction of differentiation by 1,25-dihydroxyvitamin D3 U. Weidmann E. Krapohl A. Schneider B. Karakas T. Bergmann L. Proc. Am. Assoc. Cancer Res. 1999; 40: 736Google Scholar, H. K. B. Rauscher III, F.J. U. 1998; PubMed Scopus Google Scholar). The of the be by a cell or of the VDR gene expression by WT1. regulation of has been H. E. S. K. E. 1997; PubMed Scopus Google Scholar), this at the in Wilms' tumors pointed to a tumor suppressor function of WT1. This is by the that WT1 expression of the growth factor receptor C. S. P. C. A.J. M.R. Haber D.A. J. PubMed Scopus Google and the growth factor receptor H. Z. Rauscher III, F.J. Morris J.F. D. Cell. Biol. PubMed Scopus Google genes and the cell cycle p21 C. S. A.J. J. Haber D.A. Cancer Res. 1997; Google and the protein M. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). Our of an induction of the VDR by WT1 the that of WT1 have an influence on the response to 1,25-dihydroxyvitamin D3 with possible for suggesting a for an function of WT1 in at tumor tissues. We the of and We and for of the and Karakas for We J. Rauscher for the wt1 expression 1,25-Dihydroxyvitamin D3 was kindly provided by

References

26